Lupin gains on its arm launching generic Aciphex Delayed-Release tablets, 20 mg in the US

11 Nov 2013 Evaluate

Lupin is currently trading at Rs 886.40, up by 2.75 points or 0.31% from its previous closing of Rs 883.65 on the BSE.

The scrip opened at Rs 884.00 and has touched a high and low of Rs 891.20 and Rs 883.00 respectively. So far 22816 shares were traded on the counter.

The BSE group 'A' stock of face value Rs 2 has touched a 52 week high of Rs 946.35 on 11-Oct-2013 and a 52 week low of Rs 557.10 on 19-Nov-2012.

Last one week high and low of the scrip stood at Rs 893.85 and Rs 865.00 respectively. The current market cap of the company is Rs 39788.64 crore.

The promoters holding in the company stood at 46.78% while Institutions and Non-Institutions held 43.52% and 9.69% respectively.

Lupin’s - US subsidiary, Lupin Pharmaceuticals, has launched its generic Rabeprazole Sodium delayed?release tablets, 20mg. The company had earlier received final approval from the US FDA for the same. Lupin’s Rabeprazole Sodium delayed?release tablets, 20mg, are the generic equivalent of Eisai Inc.’s Aciphex delayed?release tablets, 20mg, and are indicated for the treatment of Gastro esophageal reflux disease (GERD). Aciphex delayed?release tablets, 20mg, had annual U.S sales of approximately $ 864.3million (IMS MAT Jun 2013).

Lupin is an innovation led transnational pharmaceutical company producing and developing a wide range of branded and generic formulations and APIs globally.

Lupin Share Price

2097.65 5.70 (0.27%)
05-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1804.95
Dr. Reddys Lab 1275.05
Cipla 1520.55
Zydus Lifesciences 931.45
Lupin 2097.65
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×